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Background: There is a paucity of evidence to support safe and effective management of 
acute severe ulcerative colitis (ASUC) in the COVID-19 pandemic period. We sought to 
identify alterations in treatment paradigms of ASUC during the early COVID-19 pandemic, 
the impact on ASUC outcomes and any associations with SARS-CoV-2 infection and severe 
COVID-19 outcomes. 
Methods: A multicentre observational case control study of ASUC patients during the first 
wave of the COVID-19 pandemic in the United Kingdom, with comparison to a 2019 pre-
pandemic historical cohort. 
Findings: We included 782 patients (398 in the pandemic period cohort and 384 in the 
historical control cohort) meeting the Truelove and Witts criteria for ASUC. The primary 
outcome of rescue therapy (including primary induction) or surgery was higher during the 
pandemic (55·2% [217/393] vs 41·8% [159/380] p=0·00024) and the time to the primary 
outcome was shorter (p = 0·0026). During the pandemic more patients received ambulatory 
(outpatient) intravenous steroids (13·2% [51/385] vs 5·3% [19/360] respectively, 
p=0·00023). During the pandemic, more patients received induction biologic therapy (either 
as rescue or primary therapy), ciclosporin or tofacitinib (45·7% [177/387] vs 35·9% 
[134/373], p=0·0064), there was lower use of thiopurines (7·3% [29/398] vs 12·0% [46/384], 
p=0·029) and 5-aminosalicylic acids (5-ASAs) (16·8% [67/398] vs 25·5% [98/384], p=0·0037). 
Whilst colectomy rates were similar between the pandemic and historical control groups 
(16·5% [64/389] vs 13·3% [50/375], p=0·26), laparoscopic surgery was less frequently 
performed during the pandemic period (53·1% [34/64] vs 76·0% [38/50], p=0·018). During 
the ASUC episode and by 3 months respectively, only 1·98% (5/253) and 1·94% (2/103) of 
patients were diagnosed with COVID-19 and none had serious COVID-19 outcomes 
(mechanical ventilation, ICU admission or death). 
Interpretation: The COVID-19 pandemic altered practice patterns of gastroenterologists and 
colorectal surgeons in the management of ASUC but was associated with similar ASUC 
outcomes to a historical cohort. Despite continued use of high dose corticosteroids and 
biologics the incidence of COVID-19 within 3-months was low and not associated with 
adverse COVID-19 outcomes. 
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Research in context 
 
Evidence before this study 
• Expert consensus exercises have indicated a lack of evidence to support safe and 
effective management of acute severe ulcerative colitis (ASUC) in the COVID-19 
pandemic period.   
• Based on the immunomodulatory properties of standard treatments for ASUC, 
there are theoretical concerns around vulnerability of patients to SARS-CoV-2 
infection and poorer outcomes from COVID-19. 
• Potential risk factors relevant to ASUC included severely active mucosal 
inflammation, nosocomial infection, as well as the use of corticosteroids and 
immunosuppressants.  
 
Added value of this study 
• During the first COVID-19 pandemic wave there were adaptations to ASUC practice 
including use of ambulatory pathways, greater use of rescue therapy and lower 
use of laparoscopic surgery. 
• Outcomes from medical and surgical management of ASUC during the first wave 
COVID-19 pandemic were similar to a pre-pandemic control cohort. 
• There was low incidence of COVID-19 in hospitalised and ambulant ASUC patients 
treated with steroids +/- biologics or small molecules during the acute episode and 
up to 90 days from ASUC diagnosis. 
• In this group of patients with a high inflammatory burden treated with powerful 
immunosuppression no severe COVID-19 outcomes were observed.  
 
Implications of all the available evidence 
• This data provides reassurance for clinicians during subsequent waves of the 
COVID-19 pandemic regarding the conventional management of ASUC using 
immune modifying drugs including use of intravenous corticosteroids and rescue 
therapies. 
• Adaptations to care pathways and the impact of SARS-CoV-2 have not been seen 
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to be detrimental to overall patient outcome in ASUC and support the shaping of 
future care pathways in subsequent waves of this pandemic. Prospective studies 
are recommended embedding current and innovative changes to care pathways 








The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has challenged conventional treatment strategies of inflammatory bowel disease 
(IBD) including the management of patients with acute severe ulcerative colitis (ASUC). 
ASUC is most commonly defined by the Truelove and Witts criteria,1 which combines 
frequency of bloody stools (≥6 per day) with markers of systemic toxicity. Approximately 
20–30% of patients with ulcerative colitis (UC) require hospitalization at some point in their 
disease course for an acute severe flare2,3 and prior to the COVID-19 pandemic, ASUC was 
associated with a mortality of 1-2·9%.2,4 
Data from small cohorts in the first wave of the COVID-19 pandemic suggested that disease 
activity may be a predictor for adverse COVID-19 outcomes in IBD patients.5,6 Despite this, 
clinicians may have used a higher clinical threshold to determine which patients required 
emergency hospital admission due to concerns regarding nosocomial spread of SARS-CoV-
2,7 particularly in those thought to be most vulnerable to severe COVID-19 outcomes in 
whom ‘shielding’ and isolation was recommended. These concerns were shared by patients, 
whose reluctance for hospitalization may have led to failure in attendance for infusions and 
delayed presentation even in the presence of severe IBD symptoms.8,9 
Pandemic-related challenges persisted after presentation to secondary care with ASUC; 
recommended early endoscopic mucosal assessment may have been impacted by 
uncertainty and delays regarding potential viral shedding in faeces, pre-endoscopic viral 
screening, availability of personal protective equipment (PPE), endoscopic capacity and 
staffing shortages.10,11  
Conflicting evidence on the impact of high dose steroids in SARS-CoV-2 infection and COVID-
1912,13 challenged conventional steroid treatment dosing strategies.  Data to inform 
discussions and decisions regarding risk:benefit of drugs used as rescue therapy, such as 
infliximab and ciclosporin in the pandemic era are still emerging.13,14 Furthermore, early 
evidence from the pandemic identified that contracting COVID-19 in the peri-operative 
period increased mortality substantially, and this may subsequently have encouraged 
surgeons to set higher thresholds for considering colectomy15 and also debate the role of 
laparoscopic surgery.16 
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Many of the current guidance documents relating to IBD care during the COVID-19 
pandemic, including ASUC are based on expert consensus supported by few, if any, 
published data.17,18 The impact of potential changes to conventional management pathways 
on ASUC outcomes is uncertain. A RAND consensus panel from the British Society of 
Gastroenterology (BSG) issued an expert consensus19 pending evidence, acknowledging that 
there are considerable areas of uncertainty in relation to risk stratifying and managing ASUC 
patients in the era of the COVID-19 pandemic. The panel also suggested that this may 
contribute to variability in practice patterns and differences in patient outcomes. 
The aim of this study was to identify alterations to established conventional evidence-based 
management of ASUC as a consequence of the first wave of the COVID-19 pandemic in the 
UK, and to evaluate the impact on patient outcomes and COVID-19 acquisition and severity. 
  




Study Cohorts  
PROTECT-ASUC (COVID-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in 
Acute Severe Ulcerative Colitis) was a multi-centre observational case-control study 
conducted in acute secondary care hospitals throughout the United Kingdom (UK). We 
included adult patients (age ≥ 18 years) with either ulcerative colitis (UC) or inflammatory 
bowel disease unclassified (IBD-U) presenting with ASUC who fulfilled the Truelove and 
Witts criteria.1  
Cases and controls were identified as either admitted or managed in emergency ambulatory 
care settings between 1st March 2020 and 30th June 2020 (COVID-19 pandemic period 
cohort), or between 1st January 2019 and 30th June 2019, (historical control cohort) 
respectively. Sites were asked to identify consecutive patients. Patients with Crohn’s 
disease, infective colitis, cytomegalovirus (CMV) or Clostridium difficile infections were 
excluded from the study. Patients were identified from the participating site admission 
clinical records and IBD databases. 
Data collection 
We collected baseline clinical information including demographics (age, gender, ethnicity, 
body mass index and smoking status), disease characteristics (disease duration, disease 
extent, prior treatments including steroid, immunomodulatory and biologic therapies), 
disease severity markers (C-reactive protein, serum albumin, haemoglobin, C-reactive 
protein–albumin ratio, endoscopic severity) and testing for SARS-CoV-2. 
Following diagnosis of ASUC, details of steroid therapy including preparation, dose duration, 
and clinical setting where instituted and continued (ambulatory outpatient care or 
inpatient), need for, and drug(s) prescribed as rescue therapy, as well as need for 
emergency colectomy during index admission were recorded.  Data on therapies including 
5-ASAs, steroids, immunomodulators either discontinued or initiated during the ASUC 
admission/period were recorded.   Follow-up data were collected at 3 months with day of 
initial admission marked as day 0, and included clinical and biomarker remission status of 
IBD (where available), change in therapy during follow up and need for colectomy.   
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COVID-19 diagnoses at the point of ASUC diagnosis, nosocomial development of COVID-19 
and COVID-19 acquisition between hospital discharge and 3-month follow up were 
recorded, including whether a diagnosis was based on symptoms, SARS-CoV-2 serology or 
quantitative Polymerase Chain Reaction (qPCR). 
All clinical data were collected pseudo-anonymised and entered into a secure central 
REDCap server hosted at the Royal Devon and Exeter NHS Foundation Trust, UK. 
Outcomes of interest 
The primary outcome was the proportion of patients with ASUC receiving rescue therapy 
(including primary induction) and/or colectomy. Secondary outcome measures, both during 
ASUC episode and at 3-month follow up, included: time to rescue therapy or surgery, time 
to colectomy, new drugs prior to discharge, length of hospital admission, death during ASUC 
episode, adverse events (post‐operative complications and mortality), positive PCR for 
SARS-CoV-2 and serious outcomes from COVID-19 (defined as the need for mechanical 
ventilation, intensive care unit [ICU] treatment or death).  
Statistical analysis 
The study was analysed and reported according to Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) methodology20 and Statistical Analysis and 
Methods in the Published Literature (SAMPL).21 Non-parametric data were summarised as 
medians and interquartile ranges (IQR) and differences between current pandemic cohort 
cases and historic cohort controls analysed using the Mann‐Whitney U test. Categorical 
variables were summarised as proportions and analysed by Fisher's exact test or chi‐squared 
test as appropriate; firstly, for initial outcomes after ASUC and secondly for 3-month follow 
up data.  
Kaplan‐Meier survival curves were plotted for i) rescue therapy or colectomy, and ii) 
colectomy rates in the cases and controls in the first 30 days after ASUC diagnosis. We used 
a combined outcome of rescue therapy or colectomy in preference of rescue therapy alone 
in order to avoid the incorrect assignment of patients who went straight-to-surgery as 
having `survived` without rescue therapy when no such therapy would be possible.  All tests 
were two‐sided and a P value of <0·05 was considered significant with no correction made 
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for multiple tests. Analysis was carried out using R 4·0·2 (R Foundation for Statistical 
Computing, Vienna, Austria) and the survival package.  
Clinically plausible and previously reported markers of disease severity22 in acute severe 
colitis (stool frequency, C-reactive protein, haemoglobin, albumin, CRP/albumin ratio) were 
selected for univariable (UVA) and multivariable (MVA) logistic regression models for the 
primary outcome of interest: rescue therapy (including primary induction) or surgery. In the 
MVA we present all terms without a reductive model as our intention was to establish if 
case-control status influenced outcome independently of markers for disease severity. 
These findings informed a sensitivity analysis using complete cases and after propensity 
score matching using the MatchIt package.23 The covariates included were day 0 stool 
frequency, log(CRP) and albumin. 
Ethical considerations 
This study was registered with research governance teams at all hospital sites to approve 
access to patient records. The study was approved by Leeds and Bradford ethics committee 
(IRAS No:284030, REC reference:20/HRA/2578) and the protocol listed at 
https://clinicaltrials.gov/ct2/show/NCT04411784). As no additional study procedures were 
carried out the need for written informed consent was waived by the ethics committee. 
Role of the funding source 
There was no funding for this study. All authors had full access to all the data in the study 









A total of 834 consecutive patients fulfilling the criteria for ASUC were submitted by 60 UK 
centres. Fifty-two patients were excluded from the final analysis:   COVID-19 at baseline 
(n=1); admission outside of the specified periods (n=6); patients received neither 
intravenous steroids nor rescue therapy (n=19); acute CMV colitis (n=10); and, Clostridium 
difficile associated diarrhoea (n=16).  Seven hundred and eighty-two patients were used in 
the final analysis (398 COVID-19 pandemic period cases and 384 historical controls) (see 
Supplementary Figure 1). 
 
Demographics  
The baseline demographic, smoking and co-morbidities among the pandemic period cohort 
and the historical control cohort were comparable and are depicted in Table 1.  
 
Disease characteristics and baseline medications  
The disease characteristics in the two cohorts were comparable (Table 1). At the time of 
presentation with ASUC, a higher proportion of patients during the COVID-19 period were 
receiving oral steroids (38·7% [148/382] vs. 25·8% [95/368], respectively, p = 0·0015), rectal 
steroids (4·8% [19/398] vs. 2·1% [8/384], respectively, p = 0·049) and biologic/small 
molecule therapies (26·9% [107/398] vs. 18·2% [70/384], p = 0·0047) than patients in the 
historic cohort. The median (IQR) duration of oral steroids prior to meeting ASUC criteria 
was 14·0 days (IQR 7·0 - 28·2) vs. 13·5 days (IQR 7·0 – 25·0) for the COVID-19 and historic 
cohorts, respectively (p = 0·21). No difference was observed in the use of oral (p = 0·94) or 
topical mesalazines (p = 0·67) or thiopurines (p = 0·55). Additionally, among patients 
receiving oral steroids, no difference in the type of steroid (prednisolone vs. poorly 
bioavailable steroid [budesonide CR, budesonide MMX or beclomethasone dipropionate]) 
used was observed between the cohorts (p = 0·17). 
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Disease severity indicators  
There was no difference at day 1, day 3 or day 5 in any established markers of ASUC severity 
(stool frequency, CRP, haemoglobin, albumin, CRP/albumin ratio) between the two cohorts 
with the exception of serum albumin levels, which were lower in the COVID-19 pandemic 
period cohort (Supplementary Table 2). 
 
Hospital Care  
A greater proportion of patients in the COVID-19 pandemic cohort in comparison to patients 
in the historic control cohort were managed initially on an ambulatory pathway (13·2% 
[51/385] vs. 5·3% [19/360], respectively, p = 0·00023; Table 2). However, 43 of 51 (84.3%) 
and 18 of 19 (94.7%) ambulatory patients in the COVID-19 and historic cohort respectively, 
required inpatient admission (p = 0.43). Patients were less likely to present emergently to 
the Accident & Emergency department (74·9% [295/394] vs. 84·5% [322/381], respectively, 
p = 0·00095) in the COVID-19 period as compared with the historic cohort. 
 
Primary and secondary outcomes 
The ASUC outcomes including outcomes from medical and surgical treatments the two 
cohorts are depicted in Table 3, and Supplementary Figure 2.  The proportion of patients 
receiving rescue therapy (including primary induction) or surgery was higher during the 
pandemic relative to the historical period (55.2% [217/393] vs 41.8% [159/380] p=0.00024). 
This difference was driven by a greater use of rescue and primary induction therapies with 
biologics, ciclosporin or tofacitinib (45·7% [177/387] vs 35·9% [134/373], respectively, 
p = 0·0064) in the COVID-19 pandemic period cohort as compared to the historical control 
period cohort. In comparison there was no difference in the requirement for emergency 
surgery between the cohorts (16.5% [64/389] vs 13.3% [50/375] respectively, p = 0.26). 
 
Medical treatment  
Response to intravenous corticosteroid in the pandemic period cohort was not statistically 
different to those in the control period cohort (68·8% [264/384] vs 74·8% [282/377], 
respectively, p = 0·065). Of patients requiring rescue or induction therapies, the choice of 
agents differed among the two cohorts with a greater use of non-infliximab and non-
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ciclosporin based treatments (23.7% [42/177] vs 12.7% [17/134], respectively, p = 0·019) in 
the pandemic period cohort (Table 4). Time to rescue therapy or surgery was significantly 
different between the pandemic and historic cohorts (p = 0.0026)(Figure 1A); rescue 
therapy or surgery happened both at a higher rate and more quickly during the COVID-19 
pandemic as compared to historic control period. The overall response to rescue therapy 
was similar within the two cohorts (81·3% [139/171] cases and 79·5% [105/132] controls, p 
= 0·77). High first infliximab dose (10mg/kg) induction loading was used in 23·5% [27/115] 
and 18·5% [17/92] of patients in the pandemic period cohort and historical control period 
cohort respectively (p = 0·40) and an accelerated infliximab dosing schedule with a second 
dose administered before discharge (prior to 2-weeks) was used in 19·2% [23/120] and 
23·1% [24/104], respectively (p = 0·51).  
 
Surgery 
In addition to there being no difference in colectomy rates there was no difference in time-
to-surgery in the two cohorts (p = 0·24) (Figure 1B). However, laparoscopic surgery was less 
often performed in the pandemic period cohort when compared to the control cohort 
(53·1% [34/64] vs 76·0% [38/50], p = 0·018). There was no significant difference in the need 
for postoperative intensive care unit stay (31.6% [18/57] vs 31.1% [14/45], p = 1.0) nor in 
overall complications rates 37·3% [22/59] vs 29·2% [14/48] (p = 0·42) or specific 
complications (Supplementary Table 3).  Furthermore, there was no difference in mortality 
between the two cohorts (p = 1.0) 
In a multivariable logistic regression analysis, the odds of rescue therapy or surgery were 
lower in the historic than the COVID-19 pandemic cohort (OR 0·63, 95%CI [0·44 to 0·89], 
p = 0·0083) – this is independent of day 1 biomarkers for disease severity including: stool 
frequency, CRP, haemoglobin, albumin and albumin/CRP ratio (Supplementary Table 4 for 
univariate and multivariable analysis). Therefore, in order to ascertain if cohort type 
influenced our primary and secondary endpoints, we performed propensity score matching 
using stool frequency, CRP, haemoglobin, albumin and albumin/CRP ratio. This analysis 
demonstrates that our primary outcomes remained significant after matching for these 
variables. In the matched cohort of 281 cases and 266 controls, day 0 albumin was no longer 
significantly different (p = 0·080). In univariable logistic regression of the primary outcome 
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in the matched cohort, the univariable odds ratio for being in the historic cohort was 
0·62 (95% CI 0·44 to 0·87; p = 0·006). 
There were differences in the type of new drugs initiated during hospitalization and at 
discharge during the two periods. In particular there was higher rates of initiation of 
biologics and small molecules and lower rates of initiation of azathioprine and mesalazine.  
(Table 4, Figure 2). 
 
3-month outcomes   
Three-month follow up data were available on 697 patients (322 from the COVID-19 period 
and 375 from the control period) (Table 5). At three months, there was no difference in the 
proportion of cases or controls in clinical (43·1% [125/290] vs 42·1% [143/340], respectively, 
p = 0·96), biomarker (63·9% [163/255] vs 62·2% [191/307], respectively, p = 0·73) or 
endoscopic remission (33·3% [15/45] vs. 30·9% [25/81], respectively, p = 0·85). Nor was 
there a difference in the proportion of patients in the two cohorts who suffered a flare of 
their IBD (25·7% [79/307] vs. 27·4% [100/365], respectively, p = 0·29). The proportions in 
each cohort being initiated on oral or topical mesalazines (p = 0·67 and p = 0·23, 
respectively), oral steroids (p = 0·45) - including which type of oral steroid was prescribed 
(prednisolone vs. poorly bioavailable steroids [p = 0·67]) - and thiopurines (p=0·33) did not 
differ. Furthermore, with regards key ASUC outcome measures, the proportion of patients 
requiring re-admission for active disease (24·4% [75/307] vs. 22·3% [81/363], respectively, 
p = 0·32), IV steroids (5.9% [19/322] vs 6.1% [23/375], respectively, p = 1·0) and surgery 
(8·6% [26/301] vs. 5·3% [19/358], respectively, p = 0·12) was not significantly different 
between the two cohorts. 
 
COVID-19 in ASUC patients  
SARS-COV-2 nasopharyngeal swab testing was undertaken in 253 (63·6% [253/398]) of the 
included patients. Five patients tested PCR positive during their ASUC hospitalization (1.98% 
[5/253]). There were no serious COVID-19 outcomes. One hundred and three patients were 
re-tested for COVID-19 PCR during 3-month follow up period and 2 patients tested positive 
(1.94% [2/103]) 5 and 12 days after discharge from index admission for ASUC and both 
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recovered without serious outcomes. The details of COVID-19 PCR positive patients and 
therapies are included in Supplementary Table 5. 
Shielding data following discharge from hospital was available in 292 patients included in 
the pandemic period cohort (Supplementary Table 6). Among these 51 (17.5% [51/292]) 
confirmed to have shielded and 31 (10·6% [31/292]) confirmed not to have shielded. A 
further 102 (34.9% [102/282]) were advised to shield but not confirmed to have followed 









We report the largest series of patients diagnosed with ASUC to date in the COVID-19 
pandemic period. We identify adaptations to treatment pathways during the first pandemic 
wave relative to a 2019 pre-pandemic cohort in the UK. During the COVID-19-era we 
observed more frequent use of biologics and tofacitinib as rescue or primary induction 
therapy. We also observed a reduction in use of immunomodulators and 5-ASAs during both 
the acute episode and at the point of discharge. Our study identifies an increased use of 
ambulatory (outpatient) pathways for initial administration of intravenous steroids although 
most of these patients were still admitted to hospital. Importantly we confirm that 
conventional use of corticosteroids during the early pandemic remained prevalent and was 
not associated with either a high incidence of SARS-CoV-2 infection, nor with adverse 
outcomes in those diagnosed with COVID-19. The incidence of surgery for ASUC was not 
higher during the pandemic. However, surgical practice for medically refractory patients 
during the pandemic was modified with a reduction in laparoscopic colectomy rates. 
Reassuringly, the immediate and 3-month outcomes of ASUC during the pandemic were 
comparable to the historical control cohort. Furthermore, during a 3-month follow up 
period, there was no increase in risk of flares, readmissions or colectomies and in the 
pandemic cohort, only two COVID-19 diagnoses among 103 tested patients. 
Consensus statements and expert opinion in the early stages of the COVID-19 pandemic 
cautioned against use of high dose corticosteroids (≥20mg of prednisolone/day) in IBD 
patients due to concerns regarding adverse outcomes in COVID-19 infection.17,18,24 This was 
largely based on extrapolation and lessons from historical cohorts in the previous 
coronavirus pandemics.25 It is known that IBD patients have a higher seasonal flu risk and 
corticosteroids are an independent risk factor.26 Steroids are also a risk factor for serious or 
opportunistic infection, particularly when combined with thiopurines.27,28,29 Conversely, 
both dexamethasone and hydrocortisone with potent immune modifying effects have been 
shown as beneficial in severe COVID-19, an infection characterised by an exaggerated 
systemic inflammatory response in some patients.12,30 
Steroids were also reported to be a risk factor for adverse COVID-19 outcomes in the 
SECURE-IBD registry,13,14 which includes physician reported cases of COVID-19, and also 
from a small cohort from Italy;5 both of which hold potential for reporting bias and neither 
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systematically controlled for disease activity. These reports have understandably led to 
concerns regarding the management of ASUC patients where intravenous high dose 
corticosteroids remain the cornerstone of first line management.19 However, despite intense 
immunosuppression including use of intravenous and high dose oral corticosteroids, we 
report very low numbers of patients with concurrent COVID-19 during admission or during 
the follow up period of 90 days.   Importantly, in our study there was no reduction in the use 
of intravenous steroids in ASUC patients during the COVID-19 era in comparison to the 
historical cohort, and in longitudinal follow up we did not notice an increase in risk of SARS-
CoV-2 infection or an increased risk of serious adverse outcomes secondary to COVID-19 in 
this cohort.   
There is increasing interest on the role of cytokine-directed therapies as a treatment for 
severe COVID-19 outside of the IBD setting.31,32 Furthermore, a recent report suggests low 
prevalence of SARS-CoCV-2 seroconversion in patients with immune-mediated inflammatory 
diseases on cytokine therapies including IBD.33 In the present study we have shown an 
overall increase in the use of rescue therapies during the COVID-19 pandemic, in particular, 
the use of Janus kinase inhibition and biologics (anti-TNF, anti-IL12/23 and anti-α4β7 
integrin). The reasons for the increase use noted is likely to be multifactorial and could 
relate to delayed presentation and advanced disease,34 concerns regarding prolonged 
steroid use in early expert consensuses,18 but also wider availability and physician 
confidence in use of newer biologics over time. Importantly, the initial SECURE-IBD registry 
data13 potentially supported the use of biologics in ASUC by showing an inverse association 
with risk of hospitalization and death in COVID-19 IBD patients on anti-TNF monotherapy 
(aOR 0·9, 95% CI 0·4-2·2). Furthermore, a recent update from the SECURE-IBD registry14 
suggests increased risk of severe COVID-19 outcomes with thiopurine monotherapy and in 
combination with anti-TNFs. Consistent with concern regarding thiopurine use and 
susceptibility to viral infection, we observed lower azathioprine use in the pandemic study 
period. Additionally, and perhaps in response to the as yet unclear mechanisms 
underpinning the association with 5-ASA and severe COVID-19 outcomes in the SECURE-IBD 
registry,13,14 we also witnessed lower use of 5-ASA at the point of discharge during the 
pandemic study period. It is plausible that in addition to these safety concerns, logistical 
issues such as infusion unit capacity and the need for regular blood monitoring during the 
   
 
 20 
pandemic35 may have had a role to play in the reduction in the use of thiopurines, 
combination therapy and infusion-based biologics.  
There is increasing debate about the timing of rescue therapy in patients who are refractory 
to intravenous corticosteroids as current practice is guided by a criterion36 developed before 
the era of biologics. Our study suggests increasing and more varied use of rescue therapy 
and primary induction agents, although there no difference was observed in overall 
colectomy rates. The use of early risk stratification tools and their impact to guide timing of 
rescue therapy is being evaluated in an ongoing study (ELEVATE ASUC- NCT03907631). 
It is plausible that enhanced adherence to well publicised public health measures including 
patient access to a self-risk identification tool18 in our cohort (see Supplementary Table 6 
for shielding data) may have reduced the risk of SARS-CoV-2 acquisition, nevertheless our 
data provide some reassurance regarding the use of intravenous corticosteroids and 
induction doses of biologics during subsequent waves of the pandemic. While we did not 
systematically analyse the seroconversion rates in all our patients in this study (the subject 
of the recently launched UK CLARITY programme www.clarityibd.org), the very low rates in 
the tested patients and low rates of serious COVID-19 outcomes in the 90-day longitudinal 
follow up period is reassuring and in line with other observations.37,38 We will seek to extend 
this follow up period in a forthcoming amendment to the existing study to capture longer-
term COVID-19 risk, IBD outcomes and surveillance for the emergence of long-COVID/IBD 
immunological phenomena. 
In the non-COVID-19 setting, clinically active IBD is reported to be an independent risk 
factor for serious viral or opportunistic infections.28,29 Importantly our study does not 
support the assumption that inflamed mucosa in in the setting of ASUC is associated with 
increased risk of SARS-CoV-2 infection. In addition, although the number of patients with 
COVID-19 was small in our cohort, our study does not support data from small cohorts that 
active IBD is a risk factor for serious COVID-19 outcomes.5,6 The impact of disease activity in 
IBD on risk of COVID-19 acquisition in different IBD phenotypes is being evaluated in 
another study from our group (www.preparedibd.org).  
Colectomy is required in up to 20% of patients with ASUC.3,4 Emerging data from the 
COVIDSurg cohort15 indicates significant mortality in patients who acquired SARS-CoV-2 in 
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the perioperative period, with an understandable increase in the threshold to undertake 
surgery. COVIDSurg has not reported outcomes in emergency surgery for IBD patients.  In 
the present study there was no difference in colectomy rates in the pandemic study period 
and there were no new infections with SARS-CoV-2 in the patients requiring colectomy. In 
addition, there was no difference in mortality rates. We observed a reduction in the number 
of colectomies undertaken using a laparoscopic approach in the pandemic period reflecting 
initial concerns of transmission risk to healthcare professionals.16  
We observed an increase use in ambulatory patient pathways during the COVID-19 period 
compared with the control group. This likely reflects concern regarding nosocomial 
transmission of COVID-19 during hospital admission particularly in patients needing 
surgery.15 More frequent use of ambulatory ASUC pathways using single daily dose 
methylprednisolone with close monitoring by the specialist teams in day care centres or 
infusion units39 in the COVID-19 cohort potentially mitigate this risk, but a large proportion 
of patients subsequently still required hospital admission and so this practice should be 
further evaluated in randomised studies in the future. 
Our study has a number of strengths: to the best of our knowledge, we report the largest 
cohort of ASUC patients treated in the early COVID-19 pandemic worldwide. We collected 
detailed metadata on clinical and biochemical disease activity markers to assess association 
with COVID-19 outcomes and recruited a matched cohort of patients treated for ASUC prior 
to the pandemic onset. However, we concede our study also has a number of limitations in 
relation to study design. PROTECT-ASUC was retrospective and whilst requested patient 
selection was consecutive, it is possible that not all ASUC patients from each centre were 
captured.   This may lead to selection bias. However, baseline patient and clinical disease 
phenotypic data as well as disease severity indices apart from serum albumin levels and 
steroid intake were all well matched, and therefore justify comparison across the two time 
periods. Furthermore, using univariable and multivariable analyses we identified potential 
confounding factors associated with the need for rescue therapy or colectomy among the 
two cohorts - we then used nearest neighbour matching to confirm our principal findings 
remained significant. While the proportion of patients on steroids before ASUC was similar 
in the two cohorts, we did not have data on the dose or duration of steroids. Importantly, 
only 5 of 385 (1·3%) of the cohort were diagnosed with COVID-19. Whilst severe outcomes 
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were not identified, larger cohorts to further study associations are desirable. Due to the 
retrospective nature of this study, we acknowledge there is some missing data. It is also 
possible that adverse events from rescue therapy, surgery and post-operative infections 
may not have been captured if not systematically recorded in local electronic recorded data. 
Therefore, our results may underestimate the incidence of adverse events.  
Conclusion 
Despite theoretical concerns regarding ASUC treatments and risk of SARS-CoV-2 acquisition 
and/or severe COVID-19 outcomes, our data identifies two reassuring important 
conclusions. Firstly, while there have been some adaptations to the conventional 
management of patients during the pandemic with regards to setting for intravenous 
steroids, choice and frequency of biologic and small molecule induction/rescue therapy and 
surgical approaches to colectomy, this did not lead to different ASUC outcomes for patients. 
Secondly, the use of cornerstone medications such as high dose intravenous steroids and 
biologics in ASUC appear to pose a low risk of nosocomial and post-discharge acquisition of 
SARS-CoV-2 and of developing severe COVID-19.  
Additional large-scale prospective studies during the COVID-19 pandemic are recommended 
to confirm the low incidence of COVID-19 in this disease group and to further study COVID-
19 outcomes. The challenges faced during the pandemic may also provide the impetus for 
more formal randomised studies to evaluate the safety and effectiveness of alternative 
ASUC treatment strategies, including the use of ambulatory pathways and non-conventional 
biologic rescue therapy. 
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Figure and Table Titles and Legends 
Figure 1: A. Time to initiation of rescue therapy or surgery for ASUC within the first 30 days. 
B. Time to surgery 
Figure 2: Maintenance treatments started during acute admission 
Table 1: Summary of baseline characteristics and baseline therapies 
Table 2: Hospital care pathways for ASUC 
Table 3: Principle outcomes: medical, surgical, ICU and mortality 
Table 4: Treatments during admission and prior to discharge   





   
 
 24 
Data sharing statement 
De-identified participant data will be made available to others for meta-analysis upon 
request following Study Steering Group discussion and signing of a data access agreement. 
Requests for access to data should be made to the corresponding author and the first 
authors via the corresponding email given. The clinical protocol is available at 
https://clinicaltrials.gov/ct2/show/NCT04411784. 
 
Author contributions statement 
SS, NAK, GW, TC, KVP, SrS, AJK, JPS, NJB, NB, HAG, LCH, SJM and CAL formed the study 
steering group. SS was responsible for initial study design which was further developed by 
the steering group. NAK led methodological development and all members of the steering 
group contributed to subsequent protocol development.  SS led regulatory approvals and 
study co-ordination. The PROTECT-ASUC study group and steering group were responsible 
for local site approvals, data acquisition and data entry. NAK and GW verified the data and 
led the statistical analysis supported by all members of the steering group. SS, GW and CAL 
led the writing group. SS, GW, NAK and CAL verified the underlying data. All members of the 




We are grateful to the clinical and research teams in the participating sites for identification 
of patients, data collection and data entry. UK gastroenterology trainees and trainee 
networks (MaGNET-Mersey Gastroenterology Network, GLINT –Gastro London Investigative 
Network for Trainees, WMRIG –West Midlands Research In Gastroenterology ,GasTRIN 
NoW-Gastroenterology Trainee Research and Improvement Network North-West, OxYGEN-
The Oxford and Thames Valley Young Gastroenterologists Network  TReNDD NI- Trainee 
Research Network in Digestive Diseases Northern Ireland) were integral in data collection 
for this study. We appreciate support from Crohn’s & Colitis UK and the British Society of 
Gastroenterology for promotion of this study.  




Declarations of interest 
Professor. Shaji Sebastian reports grants from Biogen, Takeda, AbbVie, Tillotts Pharma, 
Ferring, Biohit, Advisory board fees from Takeda, AbbVie, Pharmacocosmos, Ferring, Falk 
Pharma, Cellgene, Tillots Pharma, Biohit, Janssen, personal speaker fees from AbbVie, 
Biogen, Janssen, Merck, Tillotts, Falk Pharma, outside the submitted work. Dr. Gareth 
Walker reports personal fees from AbbVie, personal fees from Falk, personal fees from 
Janssen, personal fees from Norgine, during the conduct of the study. Dr. Nicholas Kennedy 
reports personal fees from Dr Falk, personal fees from Janssen, grants and personal fees 
from Pharmacosmos, personal fees from Takeda, personal fees from Tillotts,  outside the 
submitted work. Dr. Kamal Patel reports personal fees and non-financial support from 
Janssen, personal fees and non-financial support from Abbvie, personal fees and non-
financial support from Takeda, personal fees and non-financial support from DrFalk, non-
financial support from Ferring, outside the submitted work. Dr. Sreedhar Subramanian 
reports personal fees from Celltrion, personal fees from Janssen, personal fees from Takeda, 
personal fees from Vifor pharma, personal fees from Boehringer-Ingelheim, outside the 
submitted work. Dr Alexandra Kent reports personal fees from Pfizer, personal fees from 
Celgene-BMS, personal fees from Tillotts, personal fees from Janssen, personal fees and 
non-financial support from Dr Falk, pesonal fees and non-financial support from Takeda, 
outside the submitted work. Professor. Matthew Brookes reports grants from Vifor 
International, grants from Tillotts Pharma, other from Tillotts Pharma, personal fees from 
Vifor International, outside the submitted work. Dr. Christopher Lamb reports grants from 
Genentech, grants and personal fees from Janssen, grants and personal fees from Takeda, 
grants from AbbVie, personal fees from Ferring, grants from Eli Lilly, grants from Pfizer, 
grants from Roche, grants from UCB Biopharma, grants from Sanofi Aventis, grants from 
Biogen IDEC, grants from Orion OYJ, personal fees from Dr Falk Pharma, grants from 
AstraZeneca, outside the submitted work. Dr Thomas Conley, Dr Jonathan Segal, Dr Neeraj 
Bhala, Dr Haidee Gonzalez, Dr Lucy Hicks and Dr Shameer Mehta have nothing to disclose. 
 
 




1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br 
Med J 1955; 2:1041-8. DOI: 10.1136/bmj.2.4947.1041  
2. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe 
ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012; 107:179-
94. DOI: 10.1038/ajg.2011.386  
3. Lamb CA, Kennedy NA, Raine T, et al British Society Gastroenterology consensus 
guidelines on the management of inflammatory bowel disease in adults Gut 2019;68: s1-
s106. doi:10.1136/gutjnl-2019-318484  
4. Lynch RW, Lowe D, Protheroe A, et al. Outcomes of rescue therapy in acute severe 
ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. 
Aliment Pharmacol Ther 2013; 38:935-45. https://doi.org/10.1111/apt.12473  
5. Bezzio C,Saibeni S, Variola A et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: 
an IG-IBD study Gut 2020; 0:1–5. doi:10.1136/gutjnl-2020-321411  
6. Lukin DJ, Kumar A, Hajifathalian K, et al Baseline disease activity and steroid therapy 
stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 
(2020), doi: https://doi.org/10.1053/j.gastro.2020.05.066.  
7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 
Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-
1069. doi:10.1001/jama.2020.1585  
8. D`Amico F, Rahier JF, Salvo L, et al Views of patients with inflammatory bowel disease on 
the COVID-19 pandemic: a global survey Lancet Gastroenterol Hepatol2020 Published 
OnlineMay 13, 2020 https://doi.org/10.1016/ S2468-1253(20)30151-5  
9. Wang H-G, Xie R, Ma TH et al. Excessive anxiety in IBD patients is unnecessary for COVID-
19. Clin Res Hepatol Gastroenterol (2020), https://doi.org/10.1016/j.clinre.2020.0   
10. Zuo T, Liu Q, Zhang F, et al Depicting SARS-CoV-2 faecal viral activity in association with 
gut microbiota composition in patients with COVID-19. Gut Published Online First: 20 
July 2020. doi: 10.1136/gutjnl-2020-322294   
11. Occhipinti V, Saibeni S, Sampietro GM, Pastorelli L, Impact of COVID-19 outbreak on the 
management of patients with severe IBD: a domino effect, Gastroenterology (2020), 
doi:https://doi.org/10.1053/j.gastro.2020.05.027.  
   
 
 27 
12. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-
19 — Preliminary Report. N Engl J Med 2020; DOI: 10.1056/NEJMoa2021436   
13. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF Antagonists, are 
associated with adverse COVID-19 outcomes in patients with inflammatory bowel 
diseases: Results from an International Registry, Gastroenterology (2020), 
doi: https://doi.org/10.1053/j.gastro.2020.05.032   
14. Ungaro RC, Brenner EJ, Gearry RBet al. Effect of IBD medications on COVID-19 outcomes: 
results from an international registry. Gut 2020 (Epub ahead of print:doi:10.1136/gutjnl-
2020-322539.    
15. COVIDSurg collaborative. Mortality and pulmonary complications in patients undergoing 
surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 
2020 Jul 4;396(10243):27-38. doi: 10.1016/S0140-6736(20)31182-X   
16. Simone BD, Chouillard E, Savarion SD, et al. Emergency surgery during the COVID-19 
pandemic: what you need to know for practice. Ann R Coll Surg Engl 2020; 102: 323–
332. 323–332. doi 10.1308/rcsann.2020.0097.  
17. Allez M, Fleshner P, Geary R, et al. Care of the Patient with IBD Requiring Hospitalization 
During the COVID-19 Pandemic. Journal of Crohn's and Colitis, 2020;14(supplement 
3,S775-S779. https://doi.org/10.1093/ecco-jcc/jjaa150   
18. Kennedy NA, Jones GR, Lamb CA et al. British Society of Gastroenterology guidance for 
management of inflammatory bowel disease during the COVID-19 pandemic Gut 
2020;0:1–7. doi:10.1136/gutjnl-2020-321244   
19. Din S, Kent A, Pollok RC, et al. Adaptations to the British Society of Gastroenterology 
guidelines on the management of acute severe UC in the context of the COVID-19 
pandemic: a RAND appropriateness pane Gut Epub ahead of print: [please include Day 
Month Year]. doi:10.1136/ gutjnl-2020-321927.  
20. Gharaibeh A, Koppikar S, Bonilla-Escobar FJ: Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) in the International Journal of Medical 
Students. Int J Med Stud 2014; 2:36-37, 2014. DOI: 
https://doi.org/10.5195/ijms.2014.76  
21. Lang TA, Altman DG: Basic statistical reporting for articles published in biomedical 
journals: The “Statistical Analyses and Methods in the Published Literature” or the 
SAMPL Guidelines. Int J Nurs Stud 52:5-9, 2015. DOI: 10.1016/j.ijnurstu.2014.09.006  
   
 
 28 
22. Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of 
Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients 
with Acute Severe Colitis. Dig Dis Sci 2019 ;64(5):1119-1128. doi: 10.1007/s10620-018-
5407-7. Epub 2018 Dec 7  
23. Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric 
Causal Inference. Journal of statistical software 2015;42(8):22-
29.  DOI 10.18637/jss.v042.i08  
24. Rubin DT, Abreu MT, Rai V, et al Management of patients with Crohn's disease and 
ulcerative colitis during the Coronavirus Disease-2019 Pandemic: Results of an 
international meeting. Gastroenterology 2020;159(1):6-13.e6. doi: 
10.1053/j.gastro.2020.04.002  
25. Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of drugs during previous and current 
coronavirus pandemics: Lessons for IBD. Journal of Crohn's and Colitis, 
jjaa120, https://doi.org/10.1093/ecco-jcc/jjaa120  
26. Tinsley A, Navabi S, Williams ED, et al. Increased risk of influenza and influenza-related 
complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel 
Dis 2019;10;25(2):369-376. doi: 10.1093/ibd/izy243.  
27. Naganuma M, Kunisaki R, Yoshimura N, et al. A prospective analysis of the incidence of 
and risk factors for opportunistic infections in patients with inflammatory bowel disease. 
J Gastroenterol 2013;48(5):595-900. doi: 10.1007/s00535-012-0686-9.  
28. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients 
with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.  Am J 
Gastroenterol 2012;107(9)1409-22. doi: 10.1038/ajg.2012.218  
29. Wisniewski A, Kirchgesner J, Seksik P, et al. Increased incidence of systemic serious viral 
infections in patients with inflammatory bowel disease associates with active disease 
and use of thiopurines. United Eur Gastroenterol J 2019. DOI:10. 
1177/2050640619889763.  
30. Angus CD, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on mortality and organ 
support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid 
domain randomized clinical trial. JAMA2020;324(13):1317-1329. doi: 
10.1001/jama.2020.17022.  
   
 
 29 
31. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G et al. Trials of anti-tumour 
necrosis factor therapy for COVID-19 are urgently needed. The Lancet 2020.395;1407-
1409. doi: 10.1016/S0140- 6736(20)30858-8  
32. Robinson PC, Richards D, Tanner HL, Feldman M. Accumulating evidence suggests anti-
TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rhematol 
2020; 2(11): e633-e655. https://doi.org/10.1016/S2665-9913(20)30309-X  
33. Simon D, Tascilar K, Kronke G, et al. Patients with immune-mediated inflammatory 
diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 
seroconversion Nat Commun. 2020;11(1):3774. doi: 10.1038/s41467-020-17703-6.  
34. Occhipinti V, Patorelli L. Challenges in the Care of IBD Patients During the CoViD-19 
Pandemic: Report From a “Red Zone” Area in Northern Italy. Inflammatory Bowel 
Diseases, Volume 26, Issue 6, June 2020, Pages 793–
796, https://doi.org/10.1093/ibd/izaa084  
35. Kennedy NA, Hansen R, Young L et al. Organisational changes and challenges 
for. inflammatory bowel disease services in the UK during the COVID-19 pandemic. 
Frontline Gastroenterology 2020; 11:343-350. doi:10.1136/flgastro-2020-101520   
36. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. 
Gut 1996; 38:905-10. http://dx.doi.org/10.1136/gut.38.6.905.  
37. Fumery M, Matias C, Brochot E. Seroconversion of immunoglobulins to SARS-CoV2 in 
patients with inflammatory bowel disease patients treated by biologics. J Crohns and 
Colitis 2020; jjaa154, https://doi.org/10.1093/ecco-jcc/jjaa154  
38. Norsa L, Cosimo P, Indriolo A, et al. Asymptomatic SARS-CoV-2 infection in patients with 
inflammatory bowel disease under biologic treatment. Gastroenterology (2020). 
https://doi.org/10.1053/j.gastro.2020.08.046  
39. Townsend T, Fiske J, Collins P, et al. Ambulatory Management of acute severe ulcerative 
colitis: A pandemic-driven initiative. Inflammatory Bowel Diseases, Volume 26, Issue 10, 
October 2020, Pages e112–e113, https://doi.org/10.1093/ibd/izaa231  
 
Table 1: Summary of baseline characteristics and baseline therapies  
 




 (n = 398)  
Historical control 
cohort   
(n = 384)  
Significance  
P value  
Age in years (Median, IQR)   782  38·0 (27·0 - 54·8)  36·0 (26·0 - 52·0)  0·12  
Gender          
Male  
782  
48·5% (193/398)  49·5% (190/384)  0·83  
  Female  51·5% (205/398)  50·5% (194/384)  
BMI median (IQR)  436  24·4 (21·9 - 27·4)  24·4 (20·9 - 28·4)  0·90  




67·9% (212/312)  65·7% (186/283)  0·69  
Ex-smoker  25·0% (78/312)  25·4% (72/283)  
Current smoker  7·1% (22/312)  8·8% (25/283)  
Ethnicity          
White  
686  
81.0% (294/363) 78.3% (253/323) 
0·18 
  
Asian  11.6% (42/363) 13.6% (44/323) 
Black  3.9% (14/363) 3.7% (12/323) 
Arab  1.1% (4/363) 1.2% (4/323) 
Mixed  0.3% (1/363) 2.2% (7/323) 
Other   2.2% (8/363) 0.9% (3/323) 
Comorbidities          
Hypertension  782  10·1% (40/398)  9·6% (37/384)  0·90  
Diabetes  782  6·5% (26/398)  7·8% (30/384)  0·49  
Cardiovascular disease  782  5·5% (22/398)  6·5% (25/384)  0·65  
Chronic kidney disease  782  0·8% (3/398)  1·3% (5/384)  0·50  
COPD   782  3·0% (12/398)  1·3% (5/384)  0·14  
Asthma   782  8·8% (35/398)  8·3% (32/384)  0·90  
Chronic liver disease   782  0·8% (3/398)  0·8% (3/384)  1.0  
Current malignancy  782  1·0% (4/398)  0·8% (3/384)  1.0  
Solid organ transplant  782  0·0% (0/398)  0·3% (1/384)  1.0  
Stroke     782  1·3% (5/398)  0·5% (2/384)  0·45  
Number of comorbidities          
0                     
782  
  
70·1% (279/398)  72·1% (277/384)  
0·81  
  
1  21·4% (85/398)  18·8% (72/384)  
2  5·3% (21/398)  6·0% (23/384)  
>2  3·3% (13/398)  3·1% (12/384)  
Disease duration          
 Years since 
diagnosis                        
(median, IQR)   
739  1·0 (0·0 - 5·0)  2·0 (0·0 - 6·0)  0·14  
IBD subtype          
Ulcerative colitis   782  4·5% (18/398)  4·7% (18/384)  1·0  
Inflammatory Bowel 
Unclassified  
95·5% (380/398)  95·3% (366/384)  
Disease extent          
Proctitis  709  7·4% (25/338)  8·9% (33/371)  0·57  
  Left Sided Colitis  50·0% (169/338)  46·4% (172/371)  
Extensive Colitis   42·6% (144/338)  44·7% (166/371)  
Therapies prior to ASUC          
No treatment   782  26·4% (105/398)  29·7% (114/384)  0·34  
Oral mesalazine  782  50·3% (200/398)  49·7% (191/384)  0·94  
Rectal mesalazine  782  13·8% (55/398)  12·8% (49/384)  0·67  
Rectal steroids  782  4·8% (19/398)  2·1% (8/384)  0·049  
Any oral steroid   750  38·7% (148/382)  25·8% (95/368)  0·0015  
Type of oral steroid*          
Poorly bioavailable steroid
s  
239  15·6% (23/147)  8·7% (8/92)  0·17  
Prednisolone     84·4% (124/147)  91·3% (84/92)  
Thiopurines  782  16·3% (65/398)  14·6% (56/384)  0·55  
All biologics /small molecules   782  26·9% (107/398)  18·2% (70/384)  0·0047  
Anti-TNFs  782  16·3% (65/398)  12·5% (48/384)  0·15  
Vedolizumab  782  6·8% (27/398)  4·4% (17/384)  0·16  
Ustekinumab  782  0·8% (3/398)  0·0% (0/384)  0·25  
Tofacitinib  782  3·0% (12/398)  1·6% (6/384)  0·23  
Number of previous admissions 
with ASUC  




52·7% (192/364)  56·3% (174/309)  0·70  
  1  25·3% (92/364)  25·2% (78/309)  
2  13·2% (48/364)  10·7% (33/309)  
>2  8·8% (32/364)  7·8% (24/309)  
  
Cardiovascular disease = coronary artery disease, heart failure, arrythmia; Chronic liver disease = 
primary sclerosing cholangitis, non-alcoholic fatty liver disease, cirrhosis; COPD = chronic obstructive 
pulmonary disease; ASUC = Acute Severe Ulcerative Colitis; BMI = body mass index; TNF = tumour 
necrosis factor; Poorly available corticosteroids = Beclometasone dipropionate (Clipper), Budesonide 
CR (Enterocort CR, and Budesonide MMX (Cortiment CR); Thiopurines = azathioprine, 
mercaptopurine or tioguanine; all biologics/small molecules = infliximab, adalimumab, golimumab, 
vedolizumab, tofacitinib or ustekinumab; Anti-TNFs = infliximab, adalimumab and golimumab. 
P value = Fisher’s exact test or Mann‐Whitney U test for discrete and continuous variables 
continuous, respectively. Values are displayed % (n/N) unless otherwise stated.  
  
Table 2: Hospital care pathways for ASUC  
 
Hospital care   
% (n/N)  N  
COVID-19 
pandemic period 
cohort   
(n = 398)  
Historical control 
cohort (n = 384)  Significance P value  
Patient initially managed on an 
ambulatory pathway for IV steroids*  745  13·2% (51/385)  5·3% (19/360)  0·00023  
Attended accident & emergency 
department with ASUC  775  74·9% (295/394)  84·5% (322/381)  0·00095  
Ward patient first managed when 
diagnosed with ASUC          
Dedicated GI ward    52·9% (200/380)  56·1% (212/378)  
0·42+  Non-GI ward    38·6% (148/380)  43·9% (166/378)  
GI ward converted to general 
medicine during COVID-19 period    8·5% (32/380)  -  
Reviewed by consultant 
gastroenterologist within 24 hrs of 
hospitalization  
761  80·7% (314/389)  77·2% (287/372)  0·25  
Clinician responsible for patient after 
first 24 hrs          
IBD specialist  
766  
61·0% (238/390)  57·4% (216/376)  
0·35  
  
Non-IBD gastroenterologist  24·1% (94/390)  25·0% (94/376)  
Non-gastroenterology physician  10·5% (41/390)  14·4% (54/376)  
Colorectal surgeon  3·8% (15/390)  2·4% (9/376)  
Other general surgeon  0·5% (2/390)  0·8% (3/376)  
Patient discussed at IBD MDT  759  38·2% (150/393)  38·3% (140/366)  1.0  
*ambulatory pathway = daily outpatient visits for intravenous steroids instead of admission to 
hospital. + p value for comparison of GI vs. non-GI ward. GI = gastrointestinal; IBD = inflammatory 
bowel disease; MDT = multidisciplinary team meeting; ASUC = acute severe ulcerative colitis.  
  
Table 3: Principle outcomes: medical, surgical, ICU and mortality  
  
Outcomes   
% (n/N)  N   
COVID-19 pandemic 
period cohort   
(n = 398)  
Historical control 
cohort   
(n = 384)  
Significance  
P value  
Primary endpoint   
Rescue (including primary induction) or 
surgery  773  55.2% (217/393)  41.8% (159/380)  0.00024  
Medical Therapy Outcomes  
  Received Intravenous Steroids  768  96·7% (380/393  98·4% (369/375)  0·16  
Responded to intravenous steroids  761  68·8% (264/384)  74·8% (282/377)  0·065  
  Received rescue or primary induction 
therapy  760  45·7% (177/387)  35·9% (134/373)  0·0064  
Responded to rescue therapy   303  81·3% (139/171)  79·5% (105/132)  0·77  
Surgical Outcomes  
  Required emergency surgery for ASUC  764  16·5% (64/389)  13·3% (50/375)  0·26  
  Surgery type:          
Subtotal colectomy  
116  96·9% (62/64)  100·0% (52/52)  0·50  
Diversion  3·1% (2/64)  0·0% (0/52)  
  Surgery method:          
Open  114  
  
46·9% (30/64)  24·0% (12/50)  
0·018  
Laparoscopic  53·1% (34/64)  76·0% (38/50)  
  Post-operative complications  107 37.3% (22/59) 29.2% (14/48) 0.42 
ASUC Outcomes:          
Length of stay   
Median (IQR)  673  7·0 (5·0 - 13·0)  7·0 (5·0 - 12·0)  0·99  
ICU admissions+     762  3·1% (12/382)  2·9% (11/380)  0·32  
Invasive ventilation  782  0·7% (3/398)  0·7% (3/384)  1  
NIV  764  0·5% (2/384)  1·1% (4/380)  0·45  
ECMO  782  0% (0/398)  0% (0/384)  NA  
Death  771  1·3% (5/392)  0·8% (5/379)  1  
Composite ICU/NIV/Death/ECMO  782  4·3% (17/398)  3·6% (14/384)  0·72  
ASUC: Acute Severe Ulcerative Colitis; IQR: Inter Quartile Range; ICU: Intensive Care Unit; NIV: Non-
Invasive Ventilation; ECMO: Extracorporeal Membrane Oxygenation. + Not including planned post-




Table 4: Treatments during admission and prior to discharge 
   
Treatments during admission and 
prior to discharge  
COVID-19 pandemic 
period cohort (n = 398)  
  
Historical control 




P value   
Any rescue therapy  45·7% (177/387)  35·9% (134/373)  0·0064  
Infliximab   70·5% (124/176)  79·7% (106/133)  
0·021 
Adalimumab  0·6% (1/176)  2·3% (3/133)  
Ciclosporin  6·2% (11/176)  8·3% (11/133)  
Tofacitinib   7·4% (13/176)  2·3% (3/133)  
Ustekinumab  4·0% (7/176)  0·0% (0/133)  
Vedolizumab   11·4% (20/176)  7·5% (10/133)  
Dose of Infliximab        
10mg/kg  23·5% (27/115)  18·5% (17/92)  
0·40  
5mg/kg  76·5% (88/115)  81·5% (75/92)  
Was second dose Infliximab given 
prior to discharge  19·2% (23/120)  23·1% (24/104)  0·51  
  
  
Table 5: Changes to treatment at 3-month follow up   
 
Variable  
% (n/N)  N  
COVID-19 pandemic 
period cohort   








P value   
Patient’s disease status:           
Symptomatic remission  630  43·1% (125/290)  42·1% (143/340)  0·96 
Biochemical remission  562  63·9% (163/255)  62·2% (191/307)  0·73  
Endoscopic remission  126  33·3% (15/45)  30·9% (25/81)  0·85  
Flare in last 3-months  672  25·7% (79/307)  27·4% (100/365)  0·29  
New IBD therapies:           
Oral mesalazine  697  2·8% (9/322)  3·5% (13/375)  0·67  
Topical mesalazine  697  4·0% (13/322)  6·1% (23/375)  0·23  
Topical steroids  697  1·9% (6/322)  1·9% (7/375)  1.0  
IV steroids  697  5·9% (19/322)  6·1% (23/375)  1.0  
Oral steroid:  697  10·9% (35/322)  9·1% (34/375)  0·45  
Oral prednisolone  
69  
88·6% (31/35)  94·1% (32/34)  
0·67  
Poorly bioavailable steroid  11·4% (4/35)  5·9% (2/34)  
Thiopurine monotherapy  697  4·7% (15/322)  6·7% (25/375)  0·33  
Anti-TNF monotherapy  697  5·3% (17/322)  7·2% (27/375)  0·35  
Anti-TNF and IMM   697  2·2% (7/322)  2·7% (10/375)  0·81  
Vedolizumab   697  5·9% (19/322)  4·5% (17/375)  0·49  
Ustekinumab   697  0·6% (2/322)  0·2% (1/375)  0·60  
Tofacitinib   697  1·9% (6/322)  1·9% (7/375)  1.0  
Readmitted to hospital with active 
disease   670  24·4% (75/307)  22·3% (81/363)  0·32  




5·1% (4/79)  NA 
NA 
  
Active IBD AND no COVID-19 
symptoms  89·9% (71/79)  100.0% (81/81)  
COVID-19 symptoms AND no 
active IBD  5·1% (4/79)  NA  
Surgery  659  8·6% (26/301)  5·3% (19/358)  0·12  
Emergency surgery  
659  61·5% (16/26)  47·3% (9/19)  0·38  
Elective surgery  38·4% (10/26)  52·6% (10/19)  
IMM = immunomodulator (thiopurine or methotrexate); thiopurine = azathioprine, mercaptopurine 
or tioguanine; anti-TNF = anti-tumour necrosis factor; IV = intravenous; poorly available 
corticosteroids = Beclometasone dipropionate (Clipper), Budesonide CR (Enterocort CR), and 
Budesonide MMX (Cortiment CR). P value = Fisher’s exact test or Mann‐Whitney U test for discrete 
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Supplementary Table 1: PROTECT-ASUC study contributors and institutions 
Institution Contributors 


















Blackpool Teaching Hospitals NHS Foundation Trust 
Rhys Butcher 
Tom Riley 
Aye Mya Htun 














County Durham and Darlington NHS Foundation Trust Anjan Dhar Susan Ritchie 


































Hull University Teaching Hospitals NHS Trust 
Shaji Sebastian 
Haidee Aleman Gonzalez 
Jessica Lisle 
Sally Myers 









   
 

























Leeds Teaching Hospitals NHS Trust 
Christian Selinger 
Elaine Ong Ming San 
Konstantina Rosiou 










Tristan Townsend  
Thomas Conley  













Kasamu Kabiru Dawa 



















Newcastle upon Tyne Hospitals NHS Foundation Trust 
Christopher Lamb 




NHS Greater Glasgow & Clyde 











   
 









Northern Health and Social Care Trust 
Kok Leong Diong 
Leah Gilroy 
Hannah McCaughan 













Pennine Acute Hospitals NHS Trust 
Jimmy Limdi 































































St Helens and Knowsley Teaching Hospitals NHS trust Rajiv Chandy 
   
 





Stockport NHS Foundation Trust Rachel Campbell 













University Hospitals Birmingham NHS Foundation Trust 
Neeraj Bhala 




































Weston Area Health NHS Trust Andrew Bell Fenella Marley 
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Supplementary Table 2: Disease severity indicators 
Disease Severity Markers 
Median (IQR) a N 
COVID-19 pandemic period cohort 
  
(n = 398) 
Historical control cohort  




Day 1     
  Day 1 stool frequency  613 10·0 (8·0 - 15·0) 10·0 (8·0 - 15·0) 0·57 
  Day 1 CRP  707 52·0 (17·0 - 120·0) 54·0 (23·0 - 110·0) 0·86 
  Day 1 haemoglobin  706 123·0 (106·0 - 136·0) 123·0 (109·0 - 137·0) 0·28 
  Day 1 albumin  666 35·0 (29·0 - 39·0) 37·0 (31·0 - 41·0) 0·0036 
  Day 1 CRP/albumin ratio  662 1·6 (0·5 - 3·6) 1·6 (0·6 - 3·3) 0·70 
Day 3     
  Day 3 stool frequency  450 7·0 (4·0 - 10·0) 6·0 (4·0 - 9·0) 0·21 
  Day 3 CRP  613 31·9 (11·0 - 72·0) 31·0 (14·5 - 60·0) 0·70 
  Day 3 haemoglobin  617 112·0 (98·0 - 125·0) 116·0 (101·0 - 128·2) 0·12 
  Day 3 albumin 527 31·0 (26·0 - 35·5) 33·0 (29·0 - 37·2) 0·0048 
  Day 3 CRP/albumin ratio 519 1·1 (0·3 - 2·7) 1·0 (0·4 - 2·2) 0·25 
Day 5     
  Day 5 stool frequency  438 5·0 (3·0 - 8·0) 4·0 (3·0 - 8·0) 0·72 
  Day 5 CRP 570 14·0 (5·0 - 35·0) 15·0 (6·0 - 31·5) 0·82 
  Day 5 haemoglobin  577 110·0 (97·8 - 125·0) 115·0 (100·0 - 127·0) 0·063 
  Day 5 albumin  499 31·0 (25·0 - 35·0) 32·0 (28·0 - 36·0) 0·028 
  Day 5 CRP/albumin ratio  493 0·5 (0·2 - 1·4) 0·5 (0·2 - 1·0) 0·60 
Endoscopic assessment     
  Flexible sigmoidoscopy  758 75·5% (289/383) 79·2% (297/375) 0·23 
Day of endoscopic assessment 
median (IQR) 568 1·0 (0·0 - 3·0) 2·0 (0·0 - 3·0) 0·10 
Endoscopic Severity  
% (n/N) 
         Mayo 1 
         Mayo 2 













All values median (interquartile range) unless otherwise stated. IQR = interquartile range; CRP = C- Reactive Protein. P value = Fisher’s 
exact test or Mann‐Whitney U test for discrete and continuous variables continuous, respectively.  
a Units for variables: CRP - mg/L; albumin – g/L; haemoglobin - g/L; stool frequency - stools per 24 hours.  
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Supplementary Table 3: Table of post-operative complications 









Required emergency surgery for ASUC 764 16·5% (64/389)  13·3% (50/375)  0·26  
Post-operative ITU stay required 102 31·6% (18/57) 31·1% (14/45) 1·0 
Post-operative complications? 107 37·3% (22/59) 29·2% (14/48) 0·42 
Gastrointestinal complication(s) 782 2·0% (8/398) 1·8% (7/384) 1·0 
Wound complication(s) 782 1·3% (5/398) 0·0% (0/384) 0·062 
Infective complication(s) 782 2·3% (9/398) 1·3% (5/384) 0·42 
Renal and Endocrine complication(s) 782 0·3% (1/398) 0·0% (0/384) 1·0 
Cardiovascular disorder(s) 782 0·0% (0/398) 0·0% (0/384) NA 
Pulmonary complication(s) 782 0·5% (2/398) 0·3% (1/384) 1·0 
Neurological disorder(s) 782 0·3% (1/398) 0·0% (0/384) 1·0 
Small bowel obstruction 782 0·3% (1/398) 0·0% (0/384) 1·0 
Anastomotic stricture (includes peritoneal 
adhesions) 
782 0·0% (0/398) 0·0% (0/384) NA 
Pouch leak/Pouch failure 782 0·3% (1/398) 0·0% (0/384) 1.0 
Bowel perforation 782 0·3% (1/398) 0·0% (0/384) 1.0 
Ileus 782 0·8% (3/398) 0·8% (3/384) 1.0 
Ischaemic bowel 782 0·0% (0/398) 0·0% (0/384) NA 
GI bleeding 782 0·0% (0/398) 0·3% (1/384) 0·49 
Ileostomy / colostomy complication or 
malfunction 782 0·3% (1/398) 0·8% (3/384) 0·37 
Digestive organ disorders (includes acute 
hepatic failure and acute pancreatitis) 
782 0·0% (0/398) 0·0% (0/384) NA 
Fistula 782 0·0% (0/398) 0·0% (0/384) NA 
Hematoma/seroma 782 0·0% (0/398) 0·0% (0/384) NA 
Wound dehiscence and Delayed wound 
healing 782 1·3% (5/398) 0·0% (0/384) 0·062 
Iatrogenic injuries (includes foreign body 
accidentally left during procedure) 
782 0·0% (0/398) 0·0% (0/384) NA 
Sepsis and bacteraemia 782 1·3% (5/398) 0·8% (3/384) 0·73 
Abscess 782 1·0% (4/398) 0·8% (3/384) 1·0 
Wound infection 782 0·3% (1/398) 0·0% (0/384) 1·0 
Urinary tract infection 782 0·0% (0/398) 0·0% (0/384) NA 
Pneumonia and empyema 782 0·8% (3/398) 0·0% (0/384) 0·25 
Acute renal failure 782 0·0% (0/398) 0·0% (0/384) NA 
Fluid and electrolyte disorders (includes 
hypokalaemia) 
782 0·0% (0/398) 0·0% (0/384) NA 
Severe endocrine disorders (includes 
adrenal disorders, hypoglycaemic coma) 782 0·3% (1/398) 0·0% (0/384) 1·0 
Retention of urine 782 0·0% (0/398) 0·0% (0/384) NA 
Thrombosis/embolism 782 0·0% (0/398) 0·0% (0/384) NA 
Myocardial infarction 782 0·0% (0/398) 0·0% (0/384) NA 
Cardiac arrest 782 0·0% (0/398) 0·0% (0/384) NA 
Hypotension or shock 782 0·0% (0/398) 0·0% (0/384) NA 
Cardiac arrhythmias (excludes tachycardia) 782 0·0% (0/398) 0·0% (0/384) NA 
Heart failure 782 0·0% (0/398) 0·0% (0/384) NA 
Bleeding 782 1·0% (4/398) 0·3% (1/384) 0·37 
Haematoma 782 0·3% (1/398) 0·0% (0/384) 1·0 
Infection 782 3·5% (14/398) 1·3% (5/384) 0·061 
Intestinal leak 782 0·3% (1/398) 0·5% (2/384) 0·62 
Rectal stump blow out 782 0·5% (2/398) 0·0% (0/384) 0·50 
Ileus 782 1·3% (5/398) 0·8% (3/384) 0·73 
Thromboembolism (deep vein thrombosis 
or pulmonary embolus) 
769 0·3% (1/385) 0·0% (0/384) 1 
High stoma output 769  0·5% (2/385) 0·5% (2/384) 1 
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Supplementary Table 4: UVA and MVA for composite endpoint of rescue therapy (including primary induction) or surgery using Day 1 and Day 3 variables 
 
Term  
Day 1 variables 
UVA 
Day 1 variables 
MVA 
Day 3 variables 
UVA 
Day 3 variables 
MVA 
 OR OR 95%CI P value OR OR 95%CI P value OR OR 95%CI P value OR OR 95%CI P value 
Cohort type: 
historic cohort 0·60 0·43 to 0·82 0·0015 0·63 0·44 to 0·89 0·0083 0·60 0·43 to 0·82 0·0015 0·72 0·45 to 1·16 0·18 
Stool frequency 1·04 1·01 to 1·07 0·017 1·04 1·00 to 1·07 0·034 1·19 1·13 to 1·26 <0·0001 1·19 1·11 to 1·27 <0·0001 
Log[CRP] 1·08 0·95 to 1·22 0·23 0·95 0·77 to 1·16 0·59 1·17 1·03 to 1·34 0·020 1·04 0·81 to 1·38 0·81 
Haemoglobin 1·01 1·00 to 1·01 0·10 1·01 1·00 to 1·02 0·016 1·00 1·00 to 1·01 0·30 1·02 1·01 to 1·04 0·0085 
Albumin 0·96 0·94 to 0·99 0·0035 0·96 0·93 to 0·99 0·023 0·95 0·92 to 0·97 0·00029 0·93 0·89 to 0·97 0·0023 
CRP/albumin 1·11 1·04 to 1·18 0·0026 1·09 0·98 to 1·22 0·14 1·00 0·96 to 1·02 0·69 0·96 0·82 to 1·01 0·55 
 
MVA = multivariable analysis; UVA = univariable analysis; OR = odds ratio; OR 95% = 95% confidence interval for odds ratio 
Units for variables: CRP - mg/L; albumin – g/L; haemoglobin - g/L; stool frequency - stools per 24 hours
   
 
   
 
9 
















during follow up 
30 years, Male, 
Black 

















































Diabetes No prior 
treatment 
IV steroids, 
Oral -ASAs  
































Oral 5-ASA IV steroids, 
Oral 5-ASA 
















Nil 17 days (5 days 
post discharge)  
Imaging changes, 
No serious 
outcomes    
Oral steroids  
Oral 5- ASA 
Infliximab 
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 (N = 398) 
 
Social distancing measures pre-ASUC  
  No social distancing measures 12·6% (49/388) 
  Social distancing 23·7% (92/388) 
  Stringent social distancing 9·8% (38/388) 
  Shielding 20·6% (80/388) 
  Unknown 33·2% (129/388) 
COVID-19 risk according to British Society of Gastroenterology 
risk grid  
  Lowest 34·3% (133/388) 
  Moderate 26·3% (102/388) 
  Highest 39·4% (153/388) 
Shielding in the 3-month follow up period after ASUC  
  No 10·6% (31/292) 
  Advised to shield - unclear whether advice followed 34·9% (102/292) 
  Yes, confirmed to have shielded 17·5% (51/292) 
  Unsure 37·0% (108/292) 
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Supplementary Figure 1:  Study cohorts 
 
 
C. difficile = Clostridium difficile 
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Supplementary Figure 2: A. Outcomes in COVID-19 pandemic cohort and B. Historical control cohort 
A 
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